Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details Narrative)

v3.19.1
STOCKHOLDERS' EQUITY (DEFICIENCY) (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 7 Months Ended 12 Months Ended
Nov. 06, 2017
Nov. 02, 2017
Oct. 04, 2017
Sep. 30, 2017
Apr. 30, 2017
Sep. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Feb. 28, 2015
Dec. 31, 2014
Share-based compensation expense recognized             $ 889 $ 800    
Number of warrants purchased (in shares)             918,366   840,000 563,910
Exercise price of warrants (in dollars per share)                   $ 2.66
Convertible Promissory Notes [Member]                    
Number of shares issued (in shares) 361,462                  
Number of warrants purchased (in shares) 271,096                  
Exercise price of warrants (in dollars per share)       $ 5.90   $ 5.90        
Principal amount       $ 1,380   $ 1,380        
Purchase of common shares (in shares)       552,000   552,000        
Underwritten Public Offering [Member]                    
Gross proceeds from public offering $ 6,000                  
Net proceeds after deduction of underwriting and offering expenses $ 5,056                  
Exercise price of warrants (in dollars per share) $ 6.95                  
Warrant term (in years) 5 years                  
Common stocks [Member]                    
Convertible preferred stock issued (in shares)   20,987                
Number of shares issued (in shares)               897,958    
Common stocks [Member] | Underwritten Public Offering [Member]                    
Number of shares issued in public offering (in shares) 897,958         230,680        
Offering price, per share (in dollars per share) $ 4.90                  
Restricted Stock [Member] | Consultant [Member]                    
Stock issued for services (in shares)         9,000          
Share-based compensation expense recognized               $ 49    
Series C Preferred Stock [Member]                    
Convertible preferred stock issued (in shares)   172,886                
Preferred stock conversion basis             Each share of Series C Preferred stock is convertible into one share of Common stock (subject to adjustment) at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred stock into shares of Common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of Common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.      
Number of shares issued (in shares)     358,995              
Number of warrants purchased (in shares)   299,733 563,910              
Series D Preferred Stock [Member]                    
Convertible preferred stock issued (in shares)             1,000      
Preferred stock conversion basis             Each share of Series D Preferred stock is convertible into 1,000 shares of Common stock (subject to the beneficial ownership limitations and adjustment as provided in the certificate of designation) at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred stock into shares of Common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of Common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until the 61st day after such notice to the Company.      
Number of shares issued (in shares)             327 327    
Number of warrants purchased (in shares)       271,096   271,096        
Number of shares issued in public offering (in shares) 327         131        
Offering price, per share (in dollars per share) $ 0.049